SNOA Sonoma Pharmaceuticals, Inc.: Rasio rega marang prakiraan pendapatan

Logo grafis Sonoma Pharmaceuticals (SNOA)

Global logistics disruptions and sanctions are limiting the export of Sonoma Pharmaceuticals (SNOA) antiseptics to foreign markets. Business revenues rely on the implementation of Microcyn in dentistry and retail. Effective cost control by management has stabilized operational activities. The expected P/S ratio demonstrates the valuation trend relative to revenue forecasts, where the value 0.20 represents the current metric.

SNOA Sonoma Pharmaceuticals Inc.: Rasio kapitalisasi pasar marang pendapatan mangsa ngarep ing interval 04.07.2022 - 18.11.2026

Rincian metrik lan analitis perusahaan Sonoma Pharma (SNOA)

- data kapitalisasi saham perusahaan:
Ringkesan analisis perusahaan:SNOA (Sonoma Pharmaceuticals)
Sampel barang Sonoma Pharmaceuticals Inc.

The forward P/S reflects the market value of the business relative to expected sales volume, allowing investors to assess the degree of overpayment for the asset in real time. By analyzing the projected P/S of Sonoma Pharmaceuticals (SNOA), one can identify risks of undervaluation or asset overheating amid regulatory barriers and component supply disruptions that impact the revenue scalability of the pharmaceutical business.